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Abstract
Background: Hyperammonemia in patients with methylmalonic aciduria (MMA) and propionic
aciduria (PA) is caused by accumulation of propionyl-CoA which decreases the synthesis of N-
acetyl-glutamate, the natural activator of carbamyl phosphate synthetase 1. A treatment approach
with carglumic acid, the structural analogue of N-acetyl-glutamate, has been proposed to decrease
high ammonia levels encountered in MMA and PA crises.
Case presentation: We described two patients (one with MMA and one with PA) with
hyperammonemia at diagnosis. Carglumic acid, when associated with standard treatment of organic
acidurias, may be helpful in normalizing the ammonia level.
Conclusion: Even though the usual treatment which decreases toxic metabolites remains the
standard, carglumic acid could be helpful in lowering plasma ammonia levels over 400 micromol/L
more rapidly.
Background
Hyperammonemia in organic acidurias
Organic acidurias such as methylmalonic aciduria (MMA)
and propionic aciduria (PA) are autosomal recessive dis-
orders of branched-chain amino acid metabolism. High
ammonia levels are predominantly encountered in the
first six months of life. Since the 1970's, hyperammone-
mia has been known to be due to an accumulation of pro-
pionyl-CoA which decreases the synthesis of N-acetyl-
glutamate, the natural activator of carbamyl phosphate
synthetase 1 [1].
A treatment approach with carglumic acid, the structural
analogue of N-acetyl-glutamate, has been proposed to
decrease high ammonia levels encountered in MMA and
PA crises [2,3].
Case presentation
We have reported 2 cases of first occurrence of PA and
MMA with hyperammonemia who received standard
treatment and carglumic acid in addition.
Case 1
This patient, a girl born in June 1994, presented hypoto-
nia, poor feeding, dehydration (20% weight loss) and low
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tom-free interval. Laboratory studies showed metabolic
acidosis (pH 7.1; bicarbonates 9 mmol/L) with massive
ketonuria and hyperammonemia (427 micromol/L).
Intravenous treatment was started with glucose (10 g/kg/
d) and insulin (0.05 UI/kg/h), carnitine (400 mg/kg/d),
sodium benzoate (300 mg/kg/d) associated with a hyper-
caloric protein-free diet (glucose 10 g/kg/d and lipids 3,5
g/kg/d the first 12 hours, then glucose 17 g/kg/d and lip-
ids 5,5 g/kg/d) and vitamin therapy (hydroxocobalamin
and thiamine). Carglumic acid was administered at 200
mg/kg/d during 48 h. Diagnosis of MMA was confirmed
by urinary organic acid analysis (methylmalonic acid
20,000 mmol/mol creatinine).
Ammonia decreased to 153 micromol/L within 12 h and
normalized within 3.5 days, whereas methylmalonic acid
excretion decreased more slowly (figure 1).
Case 2
The second patient, a girl born in November 1997, pre-
sented hypotonia, seizures, poor feeding, dehydration,
polypnea at 8 days of age after a symptom-free interval.
Laboratory investigations revealed metabolic acidosis (pH
7; bicarbonates 3 mmol/L) with massive ketonuria and
hyperammonemia (213 micromol/L). Intravenous treat-
ment was started with glucose (9 g/kg/d) and carnitine
(400 mg/kg/d) associated with hypercaloric protein-free
diet (glucose 13 g/kg/d and lipids 3 g/kg/d the first 24
hours, then glucose 18 g/kg/d and lipids 4 g/kg/d). Acido-
sis decreased within 12 h but ketonuria remained and
ammonia level reached to 526 micromol/L. Diagnosis of
PA was confirmed by urinary organic acid analysis (meth-
ylcitrate 4.929 mmol/mol creatinine).
Carglumic acid was initially administered at 100 mg/kg
followed with 70 mg/kg/d during 48 h. Ammonia was
normalized within 36 h, whereas methylcitrate excretion
remained elevated (figure 2).
Conclusion
Neurological complications are frequently seen in
patients with organic acidurias due to deleterious effect of
toxic metabolites [4]. Therefore, the main aim of the treat-
ment must be their removal by using standard treatment
(high caloric, protein-free diet and carnitine). However,
several studies have already demonstrated the direct toxic
effect of ammonia on the central nervous system [5].
There is clearly an argument for enhancing ammonia
removal by using additional therapy.
In patient 1, standard treatment and carglumic acid were
started immediately at the time of diagnosis. The ammo-
nia level decreased more rapidly than toxic metabolite
excretion. In patient 2, the ammonia level increased after
the beginning of standard treatment and decreased when
carglumic acid was added. A strong correlation between
serum propionate and blood ammonia concentration has
been demonstrated mainly in the neonatal period [6]. In
these two cases, the use of carglumic acid seemed to have
a direct effect on ammonia removal, independently of the
toxic metabolite excretions. Carglumic acid, with stimu-
lating carbamyl phosphate synthetase 1, seems to be effi-
cient more rapidly than standard treatment only. It
enables to decrease ammonia level in the first 48 hours
until standard treatment removes toxics metabolites. Con-
sequently, non-experienced physicians should be aware
that adding carglumic acid decreases ammonia level but
does not indicate a decrease in accumulated toxic metab-
olites.
Plasma ammonia levels (black lines) and toxic metabolite excretions (grey ines) during th  course f treatment: patient 2 with propionic aciduria (PA)Figure 2
Plasma ammonia levels (black lines) and toxic metabolite 
excretions (grey lines) during the course of treatment: 
patient 2 with propionic aciduria (PA).
Plasma ammonia levels (black lines) and toxic metabolite excretions (grey ines) during th  course f treatment: patient 1 with methylmalonic aciduria (MMA)Figure 1
Plasma ammonia levels (black lines) and toxic metabolite 
excretions (grey lines) during the course of treatment: 
patient 1 with methylmalonic aciduria (MMA).Page 2 of 3
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In organic aciduria patients with acute hyperammonemia,
the clinical benefit of the use of carglumic acid has not yet
been established. Based on our clinical experience, carglu-
mic acid during 48 h seems helpful in lowering plasma
ammonia levels over 400 micromol/L. Recently, three
patients with MMA and PA have been treated for hyper-
ammonemia with carglumic acid. In each case, carglumic
acid appeared to accelerate ammonia detoxification [2,3].
Moreover, carglumic acid has been used in humans in the
treatment of N-acetyl-glutamate-synthase deficiency with
no major side effects [7].
Usual treatment remains the standard, however, carglu-
mic acid in the treatment of hyperammonemia in organic
acidurias seems to normalize ammonia level more rap-
idly. This effect should be assessed by a prospective multi-
center study.
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